These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 39016936)
1. Children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone treated on Children's Oncology Group studies. Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R Pediatr Blood Cancer; 2024 Oct; 71(10):e31200. PubMed ID: 39016936 [TBL] [Abstract][Full Text] [Related]
2. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659 [TBL] [Abstract][Full Text] [Related]
3. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080 [TBL] [Abstract][Full Text] [Related]
4. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361 [TBL] [Abstract][Full Text] [Related]
5. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children]. Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063 [No Abstract] [Full Text] [Related]
6. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457 [TBL] [Abstract][Full Text] [Related]
7. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080 [TBL] [Abstract][Full Text] [Related]
8. Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Weigel BJ; Lyden E; Anderson JR; Meyer WH; Parham DM; Rodeberg DA; Michalski JM; Hawkins DS; Arndt CA J Clin Oncol; 2016 Jan; 34(2):117-22. PubMed ID: 26503200 [TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382 [TBL] [Abstract][Full Text] [Related]
10. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125 [TBL] [Abstract][Full Text] [Related]
11. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group. Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378 [TBL] [Abstract][Full Text] [Related]
12. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR. Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M; Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424 [TBL] [Abstract][Full Text] [Related]
13. Whole Lung Irradiation in Rhabdomyosarcoma With Lung Metastases: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Luo LY; Xue W; Qumseya A; Vasquez JC; Venkatramani R; Wolden SL; Casey DL J Clin Oncol; 2024 Sep; ():JCO2400928. PubMed ID: 39255438 [TBL] [Abstract][Full Text] [Related]